Program
ibrutinib
Also written as “Ibrutinib”, “PCI-32765” and “PCI-32765 (Ibrutinib)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Waldenstrom Macroglobulinemia · Lymphoma, Large B-Cell, Diffuse · Multiple Myeloma, led by 5 companies.
Drug pageIbrutinib: every studyMany companies study it; this page follows only the 74 they lead. All 264 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 364 open or running | phase 4since Jun 14, 2017 | May 14, 2012 | Dec 31, 2026phase 3 · NCT01804686 |
| AbbVie | 341 open or running | phase 4since Jun 5, 2017 | Feb 20, 2009 | May 10, 2027phase 4 · NCT03229200 |
| Novartisits history only | 21 open or running | phase 2since May 21, 2019 | Mar 13, 2019 | Jun 30, 2027phase 2 · NCT03960840 |
| BeOne Medicinesits history only | 10 open or running | phase 3since Feb 7, 2017 | Feb 7, 2017 | none ahead |
| Oncternal Therapeuticsits history only | 10 open or running | phase 3since Jun 9, 2022 | Jun 9, 2022 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Feb 20, 2009.
- Oct 1, 2014Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT02264574 · 229 enrolled · United States, Australia, Austria and more
- Jan 16, 2015Phase 2 study in Leukemia, Myeloid, AcuteNCT02351037 · 36 enrolled · United States
- May 4, 2015Phase 3 study in Metastatic Pancreatic AdenocarcinomaNCT02436668 · 430 enrolled · United States, Belgium, France and more
- Sep 3, 2015Phase 2 study in Multiple MyelomaNCT02548962 · 11 enrolled · United States, Australia, Czechia and more
- Nov 4, 2015Phase 2 study in Carcinoma, Renal CellNCT02599324 · 263 enrolled · United States, Korea, Republic of, Spain and more
- Aug 19, 2016Phase 2 study in Multiple MyelomaNCT02902965 · 74 enrolled · Czechia, Germany, Greece and more
- Sep 20, 2016Phase 2 study in LeukemiaNCT02910583 · 323 enrolled · United States, Australia, Italy and more
- Oct 25, 20162 phase 3 studiesNCT02959944, NCT02947347
- Jun 5, 2017Phase 4 study in Lymphoma, B-CellNCT03229200 · 297 enrolled · United States, Australia, Canada and more
- Dec 12, 2018Phase 2 study in Bronchiolitis Obliterans SyndromeNCT03790332 · 59 enrolled · United States, Australia, Austria and more
- Mar 12, 2019Phase 2 study in LeukemiaNCT03873493 · 14 enrolled · United States, Australia, Austria and more
- May 4, 2020Phase 2 study in COVID-19NCT04375397 · 46 enrolled · United States
- Jul 17, 2020Phase 2 study in Lymphoma, Mantle-CellNCT04477486 · 13 enrolled · Japan
- Oct 25, 2021Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNCT05105841 · 20 enrolled · Japan
Ahead
- May 10, 2027Primary completion: phase 4 study in Lymphoma, B-CellNCT03229200
TargetBeta
“An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 34 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05105841Leukemia, Lymphocytic, Chronic, B-Cell · Japan | 2 | Completed | Oct 9, 2025 | 20 |
| NCT04477486Lymphoma, Mantle-Cell · Japan | 2 | Completed | Feb 9, 2022 | 13 |
| NCT04375397COVID-19 · United States | 2 | Completed | May 10, 2021 | 46 |
| NCT03873493Leukemia · United States, Australia, Austria and more | 2 | Completed | Nov 4, 2021 | 14 |
| NCT03790332Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 2 | Completed | Oct 9, 2025 | 59 |
| NCT03229200Lymphoma, B-Cell · United States, Australia, Canada and more | 4 | Active, not recruiting | May 10, 2027 | 297 |
| NCT02947347Lymphoma, Follicular · United States, Australia, Austria and more | 3 | Completed | Feb 21, 2024 | 445 |
| NCT02959944Bronchiolitis Obliterans Syndrome · United States, Australia, Austria and more | 3 | Completed | Mar 27, 2020 | 193 |
| NCT02910583Leukemia · United States, Australia, Italy and more | 2 | Completed | Nov 12, 2020 | 323 |
| NCT02902965Multiple Myeloma · Czechia, Germany, Greece and more | 2 | Completed | Oct 26, 2018 | 74 |
| NCT02599324Carcinoma, Renal Cell · United States, Korea, Republic of, Spain and more | 2 | Completed | Aug 20, 2021 | 263 |
| NCT02548962Multiple Myeloma · United States, Australia, Czechia and more | 2 | Terminated | Jun 13, 2018 | 11 |
| NCT02436668Metastatic Pancreatic Adenocarcinoma · United States, Belgium, France and more | 3 | Completed | Oct 2018 | 430 |
| NCT02351037Leukemia, Myeloid, Acute · United States | 2 | Terminated | Apr 2017 | 36 |
| NCT02264574Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Austria and more | 3 | Completed | Mar 26, 2018 | 229 |
| NCT02195869Graft vs Host Disease · United States | 2 | Completed | Sep 15, 2017 | 45 |
| NCT02165397Waldenstrom Macroglobulinemia · United States, Australia, Canada and more | 3 | Completed | Nov 7, 2019 | 181 |
| NCT02142049Lymphoma · United States | 2 | Completed | Aug 2017 | 35 |
| NCT02077166Lymphoma, Large B-Cell, Diffuse · United States, Belgium, Germany and more | 2 | Completed | Dec 17, 2020 | 138 |
| NCT01980628Lymphoma, B-Cell, Marginal Zone · United States, Belgium, France and more | 2 | Completed | Jul 2016 | 63 |
| NCT01980654Lymphoma, Follicular · United States | 2 | Completed | Nov 2017 | 80 |
| NCT01962792Multiple Myeloma · United States, Canada | 2 | Completed | Mar 2019 | 84 |
| NCT01744691Chronic Lymphocytic Leukemia With 17p Deletion · United States, Australia, Belgium and more | 2 | Completed | Jun 2014 | 145 |
| NCT01724346Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | Aug 18, 2023 | 269 |
| NCT01722487Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Belgium and more | 3 | Completed | May 2015 | 269 |
| NCT01578707Recurrence · United States, Australia, Austria and more | 3 | Completed | Nov 2013 | 391 |
| NCT01478581Multiple Myeloma · United States | 2 | Completed | Aug 2018 | 92 |
| NCT01325701Lymphoma, Large B-Cell, Diffuse · United States | 2 | Completed | Oct 2014 | 78 |
| NCT01292135Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Completed | Nov 2012 | 33 |
| NCT01236391Lymphoma, Mantle-Cell · United States, Germany, Poland and more | 2 | Completed | Jan 2014 | 115 |
| NCT01217749Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Jun 2013 | 71 |
| NCT01109069Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Apr 26, 2019 | 199 |
| NCT01105247Leukemia, Lymphocytic, Chronic, B-Cell · United States | 2 | Completed | Dec 2012 | 133 |
| NCT00849654Lymphoma, B-Cell · United States | 1 | Completed | Jul 2012 | 66 |
How it is read
Names in the registry
- “Ibrutinib”, 49 entries
- “PCI-32765”, 10 entries
- “ibrutinib”, 6 entries
- “PCI-32765 (Ibrutinib)”, 2 entries
- “SNX-5422 plus ibrutinib”, 2 entries
Codes read as this program: PCI32765.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 23 studies
- Lymphoma, Mantle-Cell, 8 studies
- Waldenstrom Macroglobulinemia, 5 studies
- Lymphoma, Large B-Cell, Diffuse, 4 studies
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.